SCHEMBL4471652

SCHEMBL4471652

O=S(=O)(NCC1CCCCC1)c1cccc2c(O)cccc12

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.60
MCL1 Q07820 1/20 0.60
NSD2 O96028 3/20 0.52
NPY5R Q15761 8/20 0.49
NPY1R P25929 4/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KMT2A Q03164 1/20 0.48
CDK2 P24941 1/20 0.46
AQP1 P29972 2/20 0.44
ADRA2A P08913 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPY2R P49146 1/20 0.44
NPY4R P50391 1/20 0.44
MCHR1 Q99705 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EDNRA P25101 1/20 0.43
GBA1 P04062 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4444605 0.83 NSD2 (0.74) BCL2L1MCL1NSD2
SCHEMBL4445383 0.80 BCL2L1 (0.54) BCL2L1MCL1NSD2NPY5RNPY1R
SCHEMBL4475298 0.77 SMN1; SMN2 (0.57) BCL2L1MCL1NPY5RNPY1RALDH1A1
SCHEMBL18392307 0.75 MCL1 (1.00) BCL2L1MCL1KMT2A
SCHEMBL29540004 0.75 MCL1 (1.00) BCL2L1MCL1KMT2A
SCHEMBL4483905 0.74 NSD2 (0.69) MCL1NSD2ALDH1A1CDK2
SCHEMBL7702998 0.74 MAPT (0.59) BCL2L1MCL1NPY5RNPY1RALDH1A1
SCHEMBL11705019 0.74 NPY5R (0.62) BCL2L1MCL1NSD2NPY5RNPY1R
SCHEMBL4489351 0.74 KMT2A (0.50) BCL2L1MCL1NSD2NPY5RNPY1R
SCHEMBL14606711 0.72 GBA1 (0.49) BCL2L1MCL1NSD2NPY5RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 BCL2L1 69/4885MCL1 155/4885NSD2 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.